Key result
Fixed-dose combination pills for primary CVD prevention are cost-neutral in high-income countries but costlier elsewhere.
Why the study?
CVD causes a major global burden, especially in lower income countries where affordability limits medicine use, prompting evaluation of the cost-effectiveness of an FDC pill across income groups.
Is a fixed dose combination pill cost-effective for primary prevention of cardiovascular disease across different country income groups?
Meta-Analysis
Yes
Is a fixed dose combination pill cost-effective for primary prevention of cardiovascular disease across different country income groups?
A fixed-dose combination pill for primary CVD prevention is cost-neutral in high-income countries and highly cost-effective for high-risk patients in lower- and upper-middle-income countries.
Supports adoption where cost-neutral in high-income countries; extends cost-effectiveness evidence across income strata.
Background: Cardiovascular disease (CVD) continues to impart a large burden on the global population, especially in lower income countries where affordability limits the use of cardiovascular medicines. A fixed dose combination strategy of at least 2 blood pressure lowering medications and a statin with aspirin in a single pill has been shown to reduce the risk of incident CVD by 38% in primary prevention in a recent meta-analysis. We report the in-trial (median follow-up: 5 years) cost-effectiveness of a fixed dose combination (FDC) pill in different income groups based on data from that meta-analysis. Methods: Countries were categorized using World Bank economic groups: Lower Middle Income Countries (LMIC), Upper Middle Income Countries (UMIC) and High Income Countries (HIC). Country specific costs were obtained for hospitalized events, procedures, and non-study medications (2020 USD). FDC price was based on the cheapest equivalent substitute (CES) for each component. Findings: For the CES-FDC pill versus control the difference in cost was $346 (95% CI: $294-$398) per participant in Lower Middle Income Countries, $838 (95% CI: $781-$895) in Upper Middle Income Countries and $42 (95% CI: -$155 to $239) (cost-neutral) in High Income Countries. During the study period the CES-FDC pill was associated with incremental gain in quality-adjusted life years of 0.06 (95% CI: 0.04-0.08) resulting in an incremental cost-effectiveness ratio (ICER) of $5767 (95% CI: 5735-$5799), $13,937 (95% CI: $13,893-$14,041) and $700 (95% CI: $662-$738) respectively. In subgroups analyses, the highest 10 years CVD risk subgroup had ICERs of $2033, $7322 and -$6000/QALY. Interpretation: A FDC pill produced at CES costs is cost-neutral in HIC. Governments of LMI and UMI countries should assess these results based on the ICER threshold accepted in their own country and own specific health care priorities but should consider prioritizing this strategy for patients with high 10 years CVD risk as a first step.
No takes yet. Share an insight, caveat, or question.
Lamy et al. (2024) conducted a meta-analysis in Primary prevention of cardiovascular disease. Fixed dose combination (FDC) pill vs. Control was evaluated on Incremental gain in quality-adjusted life years (QALYs) (0.06 QALY gain, 95% CI 0.04-0.08). A fixed dose combination pill for primary CVD prevention was cost-neutral in High Income Countries (ICER $700/QALY) but had higher ICERs in Lower Middle ($5767) and Upper Middle Income Countries.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: